Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 30Peritoneal Neoplasms 24Ovarian Neoplasms 24Fallopian Tube Neoplasms 13Carcinoma, Ovarian Epithelial 12Colorectal Neoplasms 11Neoplasm Metastasis 5Appendiceal Neoplasms 5Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Uterine Neoplasms 2Sarcoma 2Pseudomyxoma Peritonei 2Mesothelioma 2Hyperthermic Intraperitoneal Chemotherapy 2Gastric Adenocarcinoma 2Desmoplastic Small Round Cell Tumor 2Colonic Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Stage â…¢ Gastric Cancer 1Rhabdomyosarcoma 1Rectal Neoplasms 1Peritoneal Metastases From Gastric Cancer 1Peritoneal Metastases From Colorectal Cancer 1Peritoneal Diseases 1Pelvic Neoplasms 1Ovarian Epithelial Cancer Recurrent 1

Interventions

Pancreaticoduodenectomy 1Paclitaxel 1Mitomycin 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1Food, Formulated 1Filgrastim 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Peritoneal Diseases × Hyperthermic Intraperitoneal Chemotherapy × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡